BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner said the company has made great strides on multiple fronts as it accelerates commercial momentum for developing a national installed base of its PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems.
In a letter to shareholders, the company reported recent highlights including that the PURE EP system has now completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, the strengthening of its management team, and the launch of its NOVA-5 software which offers greater customization and smarter workflows with the aim of further driving clinical adoption.
“We strongly believe in the value of our technology and are now supported with both peer-reviewed clinical data and third-party economic data, proving the value of what we have built,” Londoner said.
READ: BioSig Technologies partners with Summit Blue Capital to provide leasing and finance program for its PURE EP System
“We are eager to continue working on our new commercialization strategy, seeing the impact our new NOVA-5 software has, and all our initiatives we are undertaking to drive shareholder value and expand PURE EP.”
The full shareholder letter can be read here.
Based in Westport, Connecticut, BioSig Technologies is a medical device company focused on the development and commercialization of its proprietary biomedical signal processing technology to extract information from physiologic signals, the PURE EP system.
Contact Emily at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie